Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: first clinical experience

Lung cancer is the leading cause of cancer-related deaths worldwide [1]. In early stage non-small cell lung cancer (NSCLC) curative intent surgery remains the cornerstone of treatment and provides the best hope for a cure. Despite the complete resection of the tumor, however, the risk of tumor relapse in nodal positive stage II and III disease is still high. The 5-year survival rate in pathologically proven N1-positive NSCLC is 49% and is even worse in patients with N2 nodal disease with 36% [2].

Source: Lung Cancer - January 20, 2021 Category: Cancer & Oncology Authors: Florian Eichhorn, Laura V. Klotz, Mark Kriegsmann, Helge Bischoff, Marc A. Schneider, Thomas Muley, Katharina Kriegsmann, Uwe Haberkorn, Claus Peter Heussel, Rajkumar Savai, Inka Zoernig, Dirk Jaeger, Michael Thomas, Hans Hoffmann, Hauke Winter, Martin E. Source Type: research